...
首页> 外文期刊>Journal of Clinical Microbiology >A Method To Prevent SARS-CoV-2 IgM False Positives in Gold Immunochromatography and Enzyme-Linked Immunosorbent Assays
【24h】

A Method To Prevent SARS-CoV-2 IgM False Positives in Gold Immunochromatography and Enzyme-Linked Immunosorbent Assays

机译:一种防止SARS-COV-2 IgM在金免疫色谱和酶联免疫吸附测定中的误报的方法

获取原文

摘要

We set out to investigate the interference factors that led to false-positive novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) IgM detection results using gold immunochromatography assay (GICA) and enzyme-linked immunosorbent assay (ELISA) and the corresponding solutions. GICA and ELISA were used to detect SARS-CoV-2 IgM in 86 serum samples, including 5 influenza A virus (Flu A) IgM-positive sera, 5 influenza B virus (Flu B) IgM-positive sera, 5 Mycoplasma pneumoniae IgM-positive sera, 5 Legionella pneumophila IgM-positive sera, 6 sera of HIV infection patients, 36 rheumatoid factor IgM (RF-IgM)-positive sera, 5 sera from hypertensive patients, 5 sera from diabetes mellitus patients, and 14 sera from novel coronavirus infection disease 19 (COVID-19) patients. ABSTRACT We set out to investigate the interference factors that led to false-positive novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) IgM detection results using gold immunochromatography assay (GICA) and enzyme-linked immunosorbent assay (ELISA) and the corresponding solutions. GICA and ELISA were used to detect SARS-CoV-2 IgM in 86 serum samples, including 5 influenza A virus (Flu A) IgM-positive sera, 5 influenza B virus (Flu B) IgM-positive sera, 5 Mycoplasma pneumoniae IgM-positive sera, 5 Legionella pneumophila IgM-positive sera, 6 sera of HIV infection patients, 36 rheumatoid factor IgM (RF-IgM)-positive sera, 5 sera from hypertensive patients, 5 sera from diabetes mellitus patients, and 14 sera from novel coronavirus infection disease 19 (COVID-19) patients. The interference factors causing false-positive reactivity with the two methods were analyzed, and the urea dissociation test was employed to dissociate the SARS-CoV-2 IgM-positive serum using the best dissociation concentration. The two methods detected positive SARS-CoV-2 IgM in 22 mid-to-high-level-RF-IgM-positive sera and 14 sera from COVID-19 patients; the other 50 sera were negative. At a urea dissociation concentration of 6?mol/liter, SARS-CoV-2 IgM results were positive in 1 mid-to-high-level-RF-IgM-positive serum and in 14 COVID-19 patient sera detected using GICA. At a urea dissociation concentration of 4?mol/liter and with affinity index (AI) levels lower than 0.371 set to negative, SARS-CoV-2 IgM results were positive in 3 mid-to-high-level-RF-IgM-positive sera and in 14 COVID-19 patient sera detected using ELISA. The presence of RF-IgM at mid-to-high levels could lead to false-positive reactivity of SARS-CoV-2 IgM detected using GICA and ELISA, and urea dissociation tests would be helpful in reducing SARS-CoV-2 IgM false-positive results.
机译:我们首先使用金免疫层析测定(GICA)和酶联免疫吸附试验(ELISA)和相应的酶联免疫吸附测定(ELISA)和相应的,研究了探测导致伪阳性新型严重急性呼吸综合征冠状病毒2(SARS-COV-2)IgM检测结果的干扰因素解决方案。 GICA和ELISA用于在86个血清样品中检测SARS-COV-2 IgM,其中包括5个流感病毒(流感A)IgM阳性血清,5个流感B病毒(Flu B)IgM阳性血清,5支原体肺炎IgM-阳性血清,5军团菌肺炎IgM阳性血清,6例艾滋病毒感染患者血清,36个类风湿因子IgM(RF-IgM) - 来自高血压患者的5例血清,糖尿病患者的5例血清,以及来自新的冠状病患者的14例血清感染疾病19(Covid-19)患者。摘要我们已经开始研究使用金免疫层析测定(GICA)和酶联免疫吸附测定(ELISA)和酶联免疫吸附测定(ELISA)和酶联的免疫急性呼吸综合征冠状病毒2(SARS-COV-2)IgM检测结果的干扰因素。相应的解决方案。 GICA和ELISA用于在86个血清样品中检测SARS-COV-2 IgM,其中包括5个流感病毒(流感A)IgM阳性血清,5个流感B病毒(Flu B)IgM阳性血清,5支原体肺炎IgM-阳性血清,5军团菌肺炎IgM阳性血清,6例艾滋病毒感染患者血清,36个类风湿因子IgM(RF-IgM) - 来自高血压患者的5例血清,糖尿病患者的5例血清,以及来自新的冠状病患者的14例血清感染疾病19(Covid-19)患者。分析了引起两种方法的伪阳性反应性的干扰因素,使用尿素离解试验使用最佳解离浓度来解离SARS-COV-2 IgM阳性血清。这两种方法检测到22例中高水平的RF-IgM阳性血清中的阳性SARS-COV-2 IgM和来自Covid-19患者的14例血清;其他50个血清是阴性的。在尿素解离浓度为6?摩尔/升,SARS-COV-2 IgM结果在1中至高水平的RF-IgM阳性血清中呈阳性,并且在使用GICA检测到的14个Covid-19患者血清中。以4〜摩尔/升的尿素解离浓度,并且具有低于0.371的亲和指数(AI)水平设定为阴性,SARS-COV-2 IgM结果为3中至高水平-RF-IgM阳性的阳性血清和14例Covid-19使用ELISA检测到的患者血清。在中高水平下存在RF-IgM可能导致使用GICA和ELISA检测到的SARS-COV-2 IgM的假阳性反应性,并且尿素解离测试将有助于减少SARS-COV-2 IGM假 - 积极的结果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号